LENZ Therapeutics, Inc. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. LENZ Therapeutics, Inc. is a commercial pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. The product received FDA approval in July 2025 and was commercially launched in the U.S. in August 2025. As of June 30, 2026, the company had 31,420,343 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $5.5 million | $7.4 million |
| Net Loss | $(31.9) million | $(73.4) million |
| Net Loss Per Share (Basic & Diluted) | $(1.02) | $(2.34) |
| Cash, Cash Equivalents, and Marketable Securities | $220.0 million (as of June 30, 2026) | $220.0 million (as of June 30, 2026) |
| Accumulated Deficit | $(300.5) million | $(300.5) million |
| Operating Cash Flow | Not explicitly stated for Q2 | $(72.3) million used |
Revenue Breakdown (Six Months Ended June 30, 2026):
- Product Sales, Net: $3.4 million
- License Revenue: $4.0 million
Expense Breakdown (Six Months Ended June 30, 2026):
- Selling, General and Administrative (SG&A): $84.3 million
- Cost of Sales: $1.4 million
- Research and Development (R&D): $0 (expenses reclassified to SG&A post-approval)
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased to $5.5 million in Q2 2026 from $5.0 million in Q2 2025. This increase was driven by the initiation of product sales ($1.7 million in Q2 2026 vs. $0 in Q2 2025) and license revenue ($3.8 million vs. $5.0 million).
- Expense Surge: SG&A expenses increased significantly to $39.4 million in Q2 2026 from $12.8 million in Q2 2025. This 208% increase was primarily due to the launch of a direct-to-consumer (DTC) marketing campaign, hiring of a sales force, and reclassification of certain regulatory and quality assurance costs from R&D to SG&A following FDA approval.
- R&D Elimination: R&D expenses dropped to zero in Q2 2026 from $9.1 million in Q2 2025, as the company transitioned from development to commercialization. Costs previously classified as R&D are now capitalized to inventory or expensed as SG&A.
- Net Loss Expansion: Net loss widened to $31.9 million in Q2 2026 from $14.9 million in Q2 2025, reflecting the ramp-up in commercialization costs.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes that existing cash, cash equivalents, and marketable securities of $220.0 million are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring significant operating losses as it expands its sales, marketing, and distribution infrastructure.
Recent Developments:
- Telehealth Launch: In July 2026, VIZZ became available via a telehealth platform, allowing for online evaluation and home delivery.
- International Licensing: The company entered into new agreements with Arrotex Pharmaceuticals (Australia/New Zealand) and Lunatus Global Medical Supplies (Middle East). Additionally, Everest Medicines acquired rights to VIZZ in Greater China from CORXEL, triggering a $1.3 million upfront payment recognized in Q2 2026.
Risks and Contingencies:
- Market Acceptance: Success depends entirely on the commercialization of VIZZ. The company faces competition from existing products (e.g., Vuity, Qlosi, Yuvezzi) and potential generic versions.
- Third-Party Reliance: The company relies on third-party manufacturers for production and third-party partners for international commercialization.
- Regulatory and Legal: Risks include potential changes in healthcare legislation (e.g., Inflation Reduction Act), FDA regulatory oversight, and intellectual property challenges.
- Capital Requirements: The company may need to raise additional capital in the future to support growth, which could result in dilution.
Key Facts for Investor Verification
- Runway: Verify the sufficiency of the $220.0 million cash position against the current burn rate of approximately $72 million per six months in operating cash flow.
- Product Sales Trajectory: Monitor the growth of product sales ($1.7 million in Q2 2026) to assess market penetration and the effectiveness of the DTC marketing campaign.
- License Milestones: Track the achievement of regulatory and sales milestones under international agreements (Everest, Lotus, Théa, Lunatus, Arrotex) which represent significant potential future revenue.
- Inventory Management: Review inventory levels ($4.1 million current) and cost of sales trends, noting the transition from "zero-cost" inventory to capitalized manufacturing costs.
- Competitive Landscape: Assess the impact of new competitors (e.g., Yuvezzi) and generic versions of Vuity on VIZZ's market share and pricing power.